Clobetasol
drug drugOn this page
Also known as SID144206935
Summary
Clobetasol (CHEMBL1201362) is an approved small-molecule anti-inflammatory drug targeting NR3C1; indicated across 11 conditions including lichen disease and graft versus host disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Targets: 1 (NR3C1)
- Indications: 11 conditions
- Clinical trials: 24
- Chemistry: 410.9 Da · C22H28ClFO4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201362 |
| Name | Clobetasol |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | yes |
| PubChem CID | 5311051 |
| ChEBI | CHEBI:205919 |
| Molecular formula | C22H28ClFO4 |
| Molecular weight | 410.9 |
| InChIKey | FCSHDIVRCWTZOX-DVTGEIKXSA-N |
SMILES: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)O)C)O)F)C
IUPAC name: (8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
ChEBI definition: A 3-oxo-Δ1,Δ4-steroid that is 16β-methylpregna-1,4-diene-3,20-dione bearing hydroxy groups at the 11β and 17α positions, fluorine at position 9, and a chlorine substituent at position 21. It is used as its 17α-propionate ester to treat various skin disorders, including exzema and psoriasis.
Pharmacological roles (ChEBI): anti-inflammatory drug, SMO receptor agonist.
Also known as: Clobetasol, clobetasol, SID144206935, CLOBETASOL
Patent coverage: 5,016 distinct patent families (18,896 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | Agonist | 9.18 | 0.9% | P04150 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): NR3C1.
Top Reactome pathways
8 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 1 | NR3C1 |
| Nuclear Receptor transcription pathway | 1 | NR3C1 |
| SUMOylation of intracellular receptors | 1 | NR3C1 |
| PTK6 Expression | 1 | NR3C1 |
| Regulation of RUNX2 expression and activity | 1 | NR3C1 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 1 | NR3C1 |
| Potential therapeutics for SARS | 1 | NR3C1 |
| Regulation of NPAS4 gene transcription | 1 | NR3C1 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| negative regulation of transcription by RNA polymerase II | 1 |
| regulation of gluconeogenesis | 1 |
| chromatin organization | 1 |
| regulation of DNA-templated transcription | 1 |
| regulation of transcription by RNA polymerase II | 1 |
| apoptotic process | 1 |
| chromosome segregation | 1 |
| signal transduction | 1 |
| glucocorticoid metabolic process | 1 |
| response to wounding | 1 |
| gene expression | 1 |
| microglia differentiation | 1 |
| adrenal gland development | 1 |
| nuclear receptor-mediated steroid hormone signaling pathway | 1 |
| regulation of glucocorticoid biosynthetic process | 1 |
Indications & clinical
Indications
10 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| lichen disease | 3 | MONDO:0006570 | EFO:1000724 |
| graft versus host disease | 3 | MONDO:0013730 | MONDO:0013730 |
| vulvar lichen sclerosus | 2 | MONDO:0006491 | EFO:1000623 |
| psoriasis | 2 | MONDO:0005083 | EFO:0000676 |
| bullous pemphigoid | 2 | MONDO:0019082 | EFO:0007187 |
| lichen planus, oral | 2 | MONDO:0043923 | EFO:0008517 |
| herpes labialis | 2 | MONDO:0043653 | MONDO:0043653 |
| toxic epidermal necrolysis | 1 | MONDO:0019810 | EFO:0004775 |
| phlebitis | 1 | MONDO:0004625 | EFO:1001395 |
| scleroderma | 1 | MONDO:0019340 | EFO:1001993 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 24.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 10 |
| PHASE4 | 3 |
| PHASE1 | 3 |
| Not specified | 3 |
| PHASE3 | 2 |
| PHASE1/PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00779792 | PHASE4 | UNKNOWN | Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Skin Irritation |
| NCT01205880 | PHASE4 | COMPLETED | Study to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis |
| NCT03453190 | PHASE4 | UNKNOWN | Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis |
| NCT00715975 | PHASE2/PHASE3 | COMPLETED | Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis |
| NCT01699412 | PHASE3 | COMPLETED | Clinical Trial With Clobetasol and Dexamethasone for Topical Treatment of Oral Lesions of Chronic Graft-versus-host Disease |
| NCT05010421 | PHASE3 | COMPLETED | Laser vs Clobetasol for Lichen Sclerosus |
| NCT06120140 | PHASE2 | ACTIVE_NOT_RECRUITING | Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib |
| NCT06742333 | PHASE2 | RECRUITING | Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation? |
| NCT07100613 | PHASE2 | RECRUITING | Mucoadhesive Modified-Release Formulations for the Topical Treatment of Symptomatic Oral Lichen Planus |
| NCT00393263 | PHASE2 | COMPLETED | Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus |
| NCT00757874 | PHASE2 | COMPLETED | Tacrolimus Versus Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus |
| NCT01407471 | PHASE2 | COMPLETED | Interest of Topical Spironolactone’s Administration to Prevent Corticoid-induced Epidermal Atrophy |
| NCT01557517 | PHASE2 | COMPLETED | Clobetasol for Oral Graft-Versus-Host Disease |
| NCT02319616 | PHASE1/PHASE2 | WITHDRAWN | Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis |
| NCT02744378 | PHASE2 | COMPLETED | Comparison of Tacrolimus 0.1% and Clobetasol 0.05% in the Management of Symptomatic Oral Lichen Planus |
| NCT03286582 | PHASE2 | TERMINATED | A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid |
| NCT04685031 | PHASE1/PHASE2 | UNKNOWN | Ointment Therapy and Prevention of Cannulation-Induced Superficial Phlebitis |
| NCT06752343 | PHASE2 | COMPLETED | A Comparison of Photodynamic Therapy and Topical Clobetasol in Treatment of Oral Lichen Planus: a Split-Mouth Randomised Controlled Study |
| NCT06504160 | PHASE1 | RECRUITING | Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) |
| NCT02680717 | PHASE1 | WITHDRAWN | Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea |
| NCT03399526 | PHASE1 | COMPLETED | 1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat |
| NCT06135402 | Not specified | RECRUITING | Comparison of Laser Treatment With Clobetasol Therapy in Patients With Lichen Sclerosus |
| NCT00470392 | Not specified | TERMINATED | Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis |
| NCT01987076 | Not specified | UNKNOWN | Comparison Between Corticosteroid and Topical Steroids in the DRESS |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
174 molecules share ≥1 primary target. Top 100 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| FULVESTRANT | ChEMBL + PubChem | Phase 4 (approved) | NR3C1 |
| PODOFILOX | ChEMBL + PubChem | Phase 4 (approved) | NR3C1 |
| REGORAFENIB | ChEMBL + PubChem | Phase 4 (approved) | NR3C1 |
| ACENOCOUMAROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| ALCLOMETASONE DIPROPIONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| AMCINONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| AMIODARONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| APREPITANT | ChEMBL | Phase 4 (approved) | NR3C1 |
| AURANOFIN | ChEMBL | Phase 4 (approved) | NR3C1 |
| BAZEDOXIFENE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BECLOMETHASONE DIPROPIONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BENZBROMARONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BETAMETHASONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BETAMETHASONE DIPROPIONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BETAMETHASONE PHOSPHORIC ACID | ChEMBL | Phase 4 (approved) | NR3C1 |
| BETAMETHASONE VALERATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BUDESONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| BUTOCONAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CANDESARTAN CILEXETIL | ChEMBL | Phase 4 (approved) | NR3C1 |
| CANRENONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CHLORMADINONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CICLESONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CLOBETASOL PROPIONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CLOFAZIMINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CLOTRIMAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| CORTISONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DANAZOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| DAUNORUBICIN | ChEMBL | Phase 4 (approved) | NR3C1 |
| DEFLAZACORT | ChEMBL | Phase 4 (approved) | NR3C1 |
| DESOGESTREL | ChEMBL | Phase 4 (approved) | NR3C1 |
| DESONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DESOXIMETASONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DESOXYCORTICOSTERONE PIVALATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DEXAMETHASONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DEXTROTHYROXINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DIENESTROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| DIETHYLSTILBESTROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| DIFLORASONE DIACETATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| DOXORUBICIN | ChEMBL | Phase 4 (approved) | NR3C1 |
| DROSPIRENONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| ECONAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| EFAVIRENZ | ChEMBL | Phase 4 (approved) | NR3C1 |
| ENZALUTAMIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| EPLERENONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| ESTRADIOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| ESTRIOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| ETHINYL ESTRADIOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| EXEMESTANE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FELODIPINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUDROCORTISONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUNISOLIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUOCINOLONE ACETONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUOCINONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUOROMETHOLONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUOXYMESTERONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLURANDRENOLIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUTICASONE FUROATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| FLUTICASONE PROPIONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| GLUCAGON | ChEMBL | Phase 4 (approved) | NR3C1 |
| HALCINONIDE | ChEMBL | Phase 4 (approved) | NR3C1 |
| HYDROCORTISONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| HYDROCORTISONE BUTYRATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| HYDROXOCOBALAMIN | ChEMBL | Phase 4 (approved) | NR3C1 |
| HYDROXYPROGESTERONE CAPROATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| IDARUBICIN | ChEMBL | Phase 4 (approved) | NR3C1 |
| ISOCONAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| ISRADIPINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| KETOCONAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| LASOFOXIFENE | ChEMBL | Phase 4 (approved) | NR3C1 |
| LOTEPREDNOL ETABONATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MASOPROCOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| MEDROXYPROGESTERONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MEDRYSONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MEGESTROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| MESTRANOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| METHYLPREDNISOLONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| METHYLPREDNISOLONE HEMISUCCINATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| METHYLTESTOSTERONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| METOPROLOL | ChEMBL | Phase 4 (approved) | NR3C1 |
| MICONAZOLE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MIFEPRISTONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MITOTANE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MOMETASONE FUROATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| MONTELUKAST | ChEMBL | Phase 4 (approved) | NR3C1 |
| NAFTOPIDIL | ChEMBL | Phase 4 (approved) | NR3C1 |
| NIMODIPINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| NISOLDIPINE | ChEMBL | Phase 4 (approved) | NR3C1 |
| NOMEGESTROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| NORETHINDRONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| NORGESTIMATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| NORGESTREL | ChEMBL | Phase 4 (approved) | NR3C1 |
| OXYMETHOLONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| PONATINIB | ChEMBL | Phase 4 (approved) | NR3C1 |
| PREDNICARBATE | ChEMBL | Phase 4 (approved) | NR3C1 |
| PREDNISOLONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| PREDNISONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| PROGESTERONE | ChEMBL | Phase 4 (approved) | NR3C1 |
| QUINESTROL | ChEMBL | Phase 4 (approved) | NR3C1 |
| RACECADOTRIL | ChEMBL | Phase 4 (approved) | NR3C1 |
| RIBOFLAVIN 5’-PHOSPHATE | ChEMBL | Phase 4 (approved) | NR3C1 |
Related Atlas pages
- Genes: NR3C1
- In clinical trials for: lichen disease, graft versus host disease, vulvar lichen sclerosus, psoriasis, bullous pemphigoid, lichen planus, oral, herpes labialis
- Drugs: Fulvestrant, Podofilox, Regorafenib, Acenocoumarol, Alclometasone Dipropionate, Amcinonide, Amiodarone, Aprepitant, Auranofin, Bazedoxifene, Beclomethasone Dipropionate, Benzbromarone, Betamethasone, Betamethasone Dipropionate, Betamethasone Phosphoric Acid, Betamethasone Valerate, Budesonide, Butoconazole, Candesartan Cilexetil, Canrenone, Chlormadinone, Ciclesonide, Clobetasol Propionate, Clofazimine, Clotrimazole, Cortisone, Danazol, Daunorubicin, Deflazacort, Desogestrel, Desonide, Desoximetasone, Desoxycorticosterone Pivalate, Dexamethasone, Dextrothyroxine, Dienestrol, Diethylstilbestrol, Diflorasone Diacetate, Doxorubicin, Drospirenone, Econazole, Efavirenz, Enzalutamide, Eplerenone, Estradiol, Estriol, Ethinyl Estradiol, Exemestane, Felodipine, Fludrocortisone, Flunisolide, Fluocinolone Acetonide, Fluocinonide, Fluorometholone, Fluoxymesterone, Flurandrenolide, Fluticasone Furoate, Fluticasone Propionate, Glucagon, Halcinonide, Hydrocortisone, Hydrocortisone Butyrate, Hydroxocobalamin, Hydroxyprogesterone Caproate, Idarubicin, Isoconazole, Isradipine, Ketoconazole, Lasofoxifene, Loteprednol Etabonate, Masoprocol, Medroxyprogesterone, Medrysone, Megestrol, Mestranol, Methylprednisolone, Methylprednisolone Hemisuccinate, Methyltestosterone, Metoprolol, Mifepristone, Mitotane, Mometasone Furoate, Montelukast, Naftopidil, Nimodipine, Nisoldipine, Norethindrone, Norgestimate, Norgestrel, Oxymetholone, Ponatinib, Prednicarbate, Prednisolone, Prednisone, Progesterone, Quinestrol, Racecadotril, RIBOFLAVIN 5’-PHOSPHATE